Real-world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years.

Patrick Huber Ulrike Förster-RuhrmannHeidi OlzeSven BeckerFriederike BärholdMandy CuevasNadine GunderJan HagemannChristoph MatthiasLudger KlimekMoritz Gröger

Published in: Allergy (2024)

The study highlights the enduring effectiveness and lack of habituation to dupilumab after a sustained therapy of 3 years, providing valuable insights into its long-term therapeutic implications for CRSwNP patients.

Keyphrases

chronic rhinosinusitis
atopic dermatitis
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
systematic review
electronic health record
stem cells
patient reported outcomes
data analysis